CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive MetabolizersS

被引:2
|
作者
Czuba, Lindsay C. [1 ]
Malhotra, Karan [2 ]
Enthoven, Luke [2 ]
Fay, Emily E. [3 ]
Moreni, Sue L. [3 ]
Mao, Jennie [3 ]
Shi, Yuanyuan [4 ]
Huang, Weize [1 ]
Totah, Rheem A. [4 ]
Isoherranen, Nina [1 ]
Hebert, Mary F. [2 ,3 ,5 ,6 ]
机构
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA USA
[2] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA USA
[4] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA USA
[5] Univ Washington, Dept Pharm, Pharm, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
[6] Univ Washington, Dept Pharm, Obstet & Gynecol, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
SMALL HETERODIMER PARTNER; BILE-ACID; AMINO-ACID; EXPRESSION; FXR;
D O I
10.1124/dmd.123.001358
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of > 20% of marketed drugs. CYP2D6 expression and activity exhibit high interindividual variability and is induced during pregnancy. The farnesoid X receptor (FXR) is a transcriptional regulator of CYP2D6 that is activated by bile acids. In pregnancy, elevated plasma bile acid concentrations are associated with maternal and fetal risks. However, modest changes in bile acid concentrations may occur during healthy pregnancy thereby altering FXR signaling. A previous study demonstrated that hepatic tissue concentrations of bile acids positively correlated with the hepatic mRNA expression of CYP2D6. This study sought to characterize the plasma bile acid metabolome in healthy women (n=47) during mid-pregnancy (25-28 weeks gestation) and {greater than or equal to} 3 months postpartum, and to determine if plasma bile acids correlate with CYP2D6 activity. It is hypothesized that during pregnancy plasma bile acids would favor less hydrophobic bile acids (cholic acid vs. chenodeoxycholic acid), and that plasma concentrations of cholic acid and its conjugates would positively correlate with the urinary ratio of dextrorphan / dextromethorphan. At 25-28 weeks gestation, taurine conjugated bile acids comprised 23% of the quantified serum bile acids compared to 7% {greater than or equal to} 3 months postpartum. Taurocholic acid positively associated with the urinary ratio of dextrorphan / dextromethorphan, a biomarker of CYP2D6 activity. Collectively, these results confirm that the bile acid plasma metabolome differs between pregnancy and postpartum and provide evidence that taurocholic acid may impact CYP2D6 activity during pregnancy.
引用
收藏
页码:1474 / 1482
页数:9
相关论文
共 50 条
  • [1] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [2] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [3] Induction of CYP2D6 in pregnancy
    Wadelius, M
    Darj, E
    Frenne, G
    Rane, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) : 400 - 407
  • [4] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [5] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [6] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [7] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [8] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Doki, Kosuke
    Sekiguchi, Yukio
    Kuga, Keisuke
    Aonuma, Kazutaka
    Homma, Masato
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 257 - 262
  • [9] CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum
    Josefsson, A
    Sydsjö, G
    Berg, G
    Dahl, ML
    Wadelius, M
    Nordin, C
    NORDIC JOURNAL OF PSYCHIATRY, 2004, 58 (01) : 61 - 64
  • [10] CHLORPHENIRAMINE PLASMA ANTAGONIST ACTIVITY IN POOR AND EXTENSIVE METABOLIZERS OF CYP2D6
    YASUDA, SU
    BARBEY, JT
    HEWETT, J
    WOOSLEY, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 170 - 170